Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol.


Journal Article

Patients with diabetes mellitus, prior myocardial infarction, older age, and a relatively preserved left ventricular ejection fraction remain at risk for sudden cardiac death that is potentially amenable by the subcutaneous implantable cardioverter defibrillator with a good risk-benefit profile. The launched MADIT S-ICD study is designed to test the hypothesis that post-myocardial infarction diabetes patients with relatively preserved ejection fraction of 36%-50% will have a survival benefit from a subcutaneous implantable cardioverter defibrillator.

Full Text

Duke Authors

Cited Authors

  • Kutyifa, V; Beck, C; Brown, MW; Cannom, D; Daubert, J; Estes, M; Greenberg, H; Goldenberg, I; Hammes, S; Huang, D; Klein, H; Knops, R; Kosiborod, M; Poole, J; Schuger, C; Singh, JP; Solomon, S; Wilber, D; Zareba, W; Moss, AJ; MADIT S-ICD Executive Committee,

Published Date

  • July 2017

Published In

Volume / Issue

  • 189 /

Start / End Page

  • 158 - 166

PubMed ID

  • 28625372

Pubmed Central ID

  • 28625372

Electronic International Standard Serial Number (EISSN)

  • 1097-6744

Digital Object Identifier (DOI)

  • 10.1016/j.ahj.2017.04.014


  • eng

Conference Location

  • United States